HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1.

Abstract : Introduction: With the aim of repositioning commercially available drugs for the inhibition of the anti-apoptotic myeloid cell leukemia protein, Mcl-1, implied in various cancers, five molecules, highlighted from a published theoretical screening, were selected to experimentally validate their affinity toward Mcl-1. Results: A detailed NMR study revealed that only two of the five tested drugs, Torsemide and Deferasirox, interacted with Mcl-1. NMR data analysis allowed the complete characterization of the binding mode of both drugs to Mcl-1, including the estimation of their affinity for Mcl-1. Biological assays evidenced that the biological activity of Torsemide was lower as compared to the Deferasirox, which was able to efficiently and selectively inhibit the antiapoptotic activity of Mcl-1. Finally, docking and molecular dynamics led to a 3D model for the Deferasirox:Mcl-1 complex and revealed the positioning of the drug in the Mcl-1 P2/P3 pockets as well as almost all synthetic Mcl-1 inhibitors. Interestingly, contrary to known synthetic Mcl-1 inhibitors which interact through Arg263, Deferasirox, establishes a salt bridge with Lys234. Conclusion: Deferasirox could be a potential candidate for drug repositioning as Mcl-1 inhibitor.
Complete list of metadata

Contributor : Muriel Sebban Connect in order to contact the contributor
Submitted on : Wednesday, February 16, 2022 - 11:47:29 AM
Last modification on : Friday, April 1, 2022 - 3:54:04 AM

Links full text



Asma Bourafai-Aziez, Mohammed Benabderrahmane, Hippolyte Paysant, Louis-Bastien Weiswald, Laurent Poulain, et al.. Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1.. Drug Design, Development and Therapy, Dove Medical Press, 2021, 15, pp.5035-5059. ⟨10.2147/dddt.s323077⟩. ⟨hal-03576776⟩



Record views